Showing results (41-50 of 121) with videos related to
Sort By:
Pageof 13
The American Journal of the Medical Sciences|June 16, 2006
Usefulness of the oximetry test for the diagnosis of sleep apnea syndrome in JapanTakayuki Takeda, Yoshihiro Nishimura, Miyako Satouchi, et al.Lung Cancer (Amsterdam, Netherlands)|September 7, 2016
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapyGiorgio Scagliotti, Makoto Nishio, Miyako Satouchi, et al.Lung Cancer (Amsterdam, Netherlands)|February 27, 2017
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancerNobuyuki Katakami, Toyoaki Hida, Hiroshi Nokihara, et al.Cancer Science|January 11, 2016
Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancerIkuo Sekine, Minako Sumi, Miyako Satouchi, et al.Cancer Science|April 27, 2017
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persistersKei Kunimasa, Tatsuya Nagano, Yohei Shimono, et al.Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)Yoshihiro Hattori, Miyako Satouchi, Nobuyuki Katakami, et al.Respiratory Investigation|August 28, 2016
Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective studyNaoto Takase, Yoshihiro Hattori, Tatsunori Kiriu, et al.Japanese Journal of Clinical Oncology|May 10, 2019
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)Akihiko Miyanaga, Kaoru Kubota, Yukio Hosomi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2023
Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)Nobuteru Kubo, Hiroaki Suefuji, Mio Nakajima, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2019
Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER studyYuki Katsuya, Hidehito Horinouchi, Takashi Seto, et al.Pageof 13